GLP-1 Medications Fuel Growth in Medical Aesthetics, with Weight Loss Accounting for 11% of Non-Surgical Spending in 2024
Guidepoint Qsight, a leader in leveraging proprietary data to provide unmatched analytics solutions, today revealed new ...
Healio21m
Novel drug confers weight loss of about 20% at 1 year in phase 2 study
Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...